Tahmasebi, 80 patient curcumin late treatment RCT: 83% lower mortality [p=0.11] https://c19p.org/tahmasebi
copied to clipboard
Nanocurcumin improves Treg cell responses in patients with mild and severe SARS-CoV2
et al., Life Sciences, doi:10.1016/j.lfs.2021.119437
RCT 40 hospitalized, 40 ICU, and 40 control patients in Iran, showing lower mortality and improved regulatory T cell responses with nanocurcumin treatment (SinaCurcumin).
|
risk of death, 83.3% lower, RR 0.17, p = 0.11, treatment 1 of 40 (2.5%), control 6 of 40 (15.0%), NNT 8.0.
|
|
risk of death, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 20 (0.0%), control 1 of 20 (5.0%), NNT 20, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), non-ICU patients.
|
|
risk of death, 80.0% lower, RR 0.20, p = 0.18, treatment 1 of 20 (5.0%), control 5 of 20 (25.0%), NNT 5.0, ICU patients.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Tahmasebi et al., 3/28/2021, Double Blind Randomized Controlled Trial, Iran, Middle East, peer-reviewed, 14 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.